Malignant Genitourinary System Neoplasm

The authors explored the viability of PAX8 expression as a biomarker for differentiating mullerian from non-mullerian tumors. 74 tumors (37 Mullerian/37 non-Mullerian) were examined for PAX8 expressio… (full text at CIViC)

PMID 24800185 · Heidarpour et al., 2014 · Open in CIViC

Among 35 patients with clear cell RCC, loss-of-function mutation of PBRM1 were correlated with response to anti-PD-1 monotherapy (P = 0.012). It was confirmed in an independent validation cohort of 63… (full text at CIViC)

PMID 29301960 · Miao et al., 2018 · Open in CIViC

Among 35 patients with clear cell RCC, loss-of-function mutation of PBRM1 were correlated with response to anti-PD-1 monotherapy (P = 0.012). It was confirmed in an independent validation cohort of 6… (full text at CIViC)

PMID 29301960 · Miao et al., 2018 · Open in CIViC

In renal clear cell carcinoma, patients with PBRM1 mutations did not have a significantly different cancer specific survival.

PMID 23620406 · Hakimi et al., 2013 · Open in CIViC

In patients with sporatic clear cell renal cell carcinoma, those with mutations in PBRM1 had better overall survival than patients with BAP1 mutations.

PMID 23333114 · Kapur et al., 2013 · Open in CIViC

Ovarian clear cell carcinoma is an aggressive and relatively chemotherapy-resistant form of ovarian cancer with a molecular landscape distinct from that of the more common epithelial subtypes. Earlier… (full text at CIViC)

PMID 19349352 · Kuo et al., 2009 · Open in CIViC

One platinum-refractory epithelial ovarian cancer patient with PTEN loss and PIK3CA amplification had a partial response on treatment with PI3K inhibitor pictilisib (GDC-0941) in this phase 1 study. A… (full text at CIViC)

PMID 25370471 · Sarker et al., 2015 · Open in CIViC

Authors tested various cervical cancer cell lines (CaSki, SiHa and HeLa) for their responses to cisplatin, radiation therapy, and GDC-0941. CaSki cells that are heterozygous for the PIK3CA-E545K mutat… (full text at CIViC)

PMID 27489350 · Arjumand et al., 2016 · Open in CIViC

Cervical cancer cell lines were treated with 1uM cisplatin followed by 1-6Gy ionizing radiation (IR). CaSki cells with PIK3CA E545K mutation show resistance to cisplatin plus IR when compared with HeL… (full text at CIViC)

PMID 27489350 · Arjumand et al., 2016 · Open in CIViC

In this study of 21 patients with FGFR-driven urothelial carcinoma treated with selective FGFR inhibitors (including erdafitinib), post-progression molecular analyses (tissue and/or ctDNA sequencing) … (full text at CIViC)

PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC

A panel of 24 endometrioid endometrial cancer (EEC) cell lines was characterized for a set of mutations and sensitivity to pan PI3K class I inhibitor GDC-0941 (pictilisib) was assessed. EEC cell lines… (full text at CIViC)

PMID 23674493 · Weigelt et al., 2013 · Open in CIViC

94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, inc… (full text at CIViC)

PMID 24166148 · Mackay et al., 2014 · Open in CIViC

This variant (R315*), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient wa… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

Case report of a patient with endometrial cancer and exceptional response to pembrolizumab (maintained at 14 months). POLE mutations V411L (exonuclease domain) and R114* were identified in the primary… (full text at CIViC)

PMID 27159395 · Mehnert et al., 2016 · Open in CIViC

In the PORTEC-3 trial cohort, POLE-ultramutated (POLEmut) endometrial carcinomas had a 98% five-year recurrence-free survival, independent of the adjuvant treatment arm. Variant P286R is the most comm… (full text at CIViC)

PMID 32749941 · León-Castillo et al., 2020 · Open in CIViC

Studies submitted to cBioPortal (including 164 TCGA studies) were evaluated for POLE variants co-occurring with features of POLE-mutated tumors and co-occurring B2M variants. A single individual with … (full text at CIViC)

PMID 29320758 · Voutsadakis, 2018 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those witho… (full text at CIViC)

PMID 17700571 · Yoshimoto et al., 2007 · Open in CIViC

PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer.

PMID 17700571 · Yoshimoto et al., 2007 · Open in CIViC

In this case study, the patient, a 54-year-old African woman, presented with pelvic pain in May 2019 and was found to have a solid heterogeneous pelvic mass with areas of fluid and hemorrhagic density… (full text at CIViC)

PMID 33970096 · Pan et al., 2021 · Open in CIViC

A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell… (full text at CIViC)

PMID 15790433 · Lee et al., 2005 · Open in CIViC

PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.

PMID 23989949 · Seront et al., 2013 · Open in CIViC

Multicenter, international, phase Ib/II trial evaluating ipatasertib 400 mg, ipatasertib 200 mg, or placebo, with abiraterone 1,000 mg orally. Combined blockade with abiraterone and ipatasertib showed…

Tumors from 35 patients (12 with partial response or stable disease) with advanced endometrial carcinoma were assessed for PTEN mutational status, revealing 12 tumors with non-identical PTEN gene muta… (full text at CIViC)

PMID 23238879 · Trédan et al., 2013 · Open in CIViC

Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100). Mice treated … (full text at CIViC)

PMID 25544636 · Schwartz et al., 2015 · Open in CIViC

A 51-year-old woman with an invasive small-cell cancer of the ureter showed a durable complete response at 3-years when treated with AZD7762 (an ATP-competitive checkpoint kinase inhibitor) and irinot… (full text at CIViC)

PMID 24934408 · Al-Ahmadie et al., 2014 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In this pre-clinical study, RAF inhibition and RAF inhibition in combination with MEK inhibition was tested in vivo in RAF1-amplified tumors (in both mice and PDX tumor models). The models were treate… (full text at CIViC)

PMID 34554931 · Bekele et al., 2021 · Open in CIViC

We have used polyclonal anti-synthetic peptide serum to study the role of retinoblastoma gene (RB) inactivation in a variety of human tumor cell lines. Our analysis indicates that inactivation of the … (full text at CIViC)

PMID 2181449 · Horowitz et al., 1990 · Open in CIViC

Analysis of cancer genome databases led to identification of a recurrent point mutation in RHEB (Y35N), reported in RCC and in several other cancers. Y35N RHEB mutation in ccRCC causes mTORC1 hyperact… (full text at CIViC)

PMID 26255626 · Ghosh et al., 2015 · Open in CIViC

After preliminary studies in cell lines, GEO datasets and fresh frozen tissues, RIT1 expression was determined in 257 tumors and 31 normal tissues. Elevated expression of RIT1 was correlated with poor… (full text at CIViC)

PMID 26617739 · Xu et al., 2015 · Open in CIViC

Vandetanib in Combination With Metformin is tested in Phase II trial in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

PMID 27325049 · Sidana et al., 2016 · Open in CIViC

In preclinical RCC models (n ≈ 5/group), Setd2 loss enhanced sensitivity to the ATR inhibitor VE822 (60 mg/kg orally, 5 days/week) and anti–PD-1 antibody (100 µg intraperitoneally, every 3 days) reduc… (full text at CIViC)

PMID 37527013 · Liu et al., 2023 · Open in CIViC

In clear cell RCC, SETD2 loss predicts sensitivity to PI3Kβ pathway inhibition: SETD2-deficient 786-0 and SETD2-mutant A498 cells treated with PI3Kβ inhibitors TGX221 or AZD8186 showed reduced viabili… (full text at CIViC)

PMID 31695846 · Terzo et al., 2019 · Open in CIViC

A 42 year old nonsmoker with metastatic lung adenocarcinoma that was wild-type for EGFR, KRAS, ROS1, and ALK, was found to have re-arranged NRG1. Treatment with afatanib resulted in rapid symptomatic … (full text at CIViC)

PMID 28502724 · Gay et al., 2017 · Open in CIViC

Two patients with EGFR/KRAS/ALK wild-type invasive mucinous adenocarcinoma of the lung were found to have SLC3A2-NRG1 fusions. Both patients were treated with combination lumretuzumab, an anti-HER3 mo… (full text at CIViC)

PMID 30268483 · Kim et al., 2018 · Open in CIViC